uniQure

$32.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.80 (-5.18%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell uniQure and other stocks, options, and ETFs commission-free!

About QURE

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands. The listed name for QURE is uniQure N.V. Ordinary Shares.

CEO
Matthew C. Kapusta
Employees
248
Headquarters
Amsterdam, Noord-Holland
Founded
1998
Market Cap
1.50B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
576.79K
High Today
$35.50
Low Today
$32.75
Open Price
$34.93
Volume
678.13K
52 Week High
$71.45
52 Week Low
$32.75

QURE News

BenzingaMar 1

uniQure Announces 2020 Financial Results and Highlights Recent Company Progress

~ Six patient procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with full enrollment of firs

QURE Earnings

-$1.21
-$0.81
-$0.40
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
-$0.01 per share

You May Also Like

MAIN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure